Two phase 2 trials, including older adults up to 75 years, have recently been published assessing the impact of retatrutide on patients with overweight and obesity, with or without T2D, respectively [75, 118]
Persistent or severe symptoms should prompt discussion with a prescribing clinician. Disclaimer This article is for educational purposes only and is not a substitute for medical advice
Today, its a software powerhouse with a technology staff of almost 11,000 people, 85% of whom are software engineers
For this indication, it is well established, with cardiovascular outcomes data to support its use
This guide covers: What the STEP clinical trials actually found Success rates at key weight loss thresholds (5%, 10%, 15%, 20%) The timeline from first injection through full results How results differ from Ozempic (same medication, different context) Factors that predict better or worse outcomes Health improvements beyond scale weight What happens when treatment stops Setting realistic expectations for your situation Key Takeaways Clinical trials show 14.9% average weight loss over 68 weeks (approximately 16 months) with Wegovy 86% of patients lose at least 5% of body weight, the threshold for clinical significance About one-third achieve 20% or greater loss , representing the dramatic transformations often highlighted Roughly 14% dont achieve meaningful results despite taking the medication as directed Timeline is gradual , with most significant progress occurring between months 4-9 at maintenance doses The dose escalation takes 16-20 weeks , meaning full effectiveness isnt reached until month 4-5 Results match Ozempic since both contain semaglutide, though Wegovys maximum dose is slightly higher (2.4mg vs
